AngioDynamics Inc. has announced the publication of the results from the PRESERVE study in European Urology, focusing on the NanoKnife® System for prostate tissue ablation in patients with intermediate-risk prostate cancer. The peer-reviewed study assessed the safety and effectiveness of irreversible electroporation and demonstrated high disease control and quality-of-life preservation, supporting its use as a focal therapy. The study's primary effectiveness endpoint was met, with 84.0% of participants free from in-field, clinically significant disease at 12 months post-procedure. Additionally, the study reported strong preservation of urinary continence and sexual function. These findings are part of a broader body of evidence from over 32 clinical studies involving more than 2,600 patients worldwide.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。